Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Royalty Pharma (NASDAQ: RPRX) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, June 10, 2025, at 2:00 p.m. ET. Investors and interested parties can access the webcast through Royalty Pharma's 'Events' page on their website at royaltypharma.com/investors/events/. The presentation will remain archived and available for viewing for at least thirty days following the event.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46^th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.   

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com

FAQ

When is Royalty Pharma (RPRX) presenting at the Goldman Sachs Healthcare Conference 2025?

Royalty Pharma will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.

How can I watch Royalty Pharma's presentation at the Goldman Sachs Conference?

The presentation can be accessed through the webcast on Royalty Pharma's 'Events' page at royaltypharma.com/investors/events/.

How long will Royalty Pharma's Goldman Sachs Conference presentation be available to view?

The webcast will be archived and available for viewing for a minimum of thirty days after the presentation.

What type of presentation will RPRX give at the Goldman Sachs Healthcare Conference?

Royalty Pharma will participate in a fireside chat format presentation at the conference.